INIS (Radnostix) ROC (Joel Greenblatt) %: -70.47% (As of Mar. 2026)


What is Radnostix ROC (Joel Greenblatt) %?

Radnostix INIS -10.25% ROC (Joel Greenblatt) % is -70.47% as of Mar. 2026. The stock has 3 warning signs investors should review. Among 983 Drug Manufacturers companies, Radnostix ranks worse than 81.79% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Radnostix's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -70.47%.

The historical rank and industry rank for Radnostix's ROC (Joel Greenblatt) % or its related term are showing as below:

INIS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -165.45   Med: -9.33   Max: 65.94
Current: -25.77

During the past 13 years, Radnostix's highest ROC (Joel Greenblatt) % was 65.94%. The lowest was -165.45%. And the median was -9.33%.

INIS's ROC (Joel Greenblatt) % is ranked worse than
81.79% of 983 companies
in the Drug Manufacturers industry
Industry Median: 11.46 vs INIS: -25.77

Radnostix's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Radnostix  (OTCPK:INIS) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Radnostix ROC (Joel Greenblatt) % Related Terms


Radnostix ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Radnostix's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radnostix ROC (Joel Greenblatt) % Chart

Radnostix Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.04 15.03 -10.09 5.81 -8.57

Radnostix Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.75 -4.49 -6.91 -19.88 -70.47

INIS vs SCYX, BTAI, IXHL: ROC (Joel Greenblatt) % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Radnostix's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Radnostix ROC (Joel Greenblatt) % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Radnostix's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Radnostix's ROC (Joel Greenblatt) % falls into.



Radnostix ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.418 + 0.875 + 0.637) - (3.235 + 0.389 + 0)
=-0.694

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1.272 + 0.832 + 0.466) - (3.521 + 0.594 + 0)
=-1.545

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Radnostix for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-5.052/( ( (7.126 + max(-0.694, 0)) + (7.212 + max(-1.545, 0)) )/ 2 )
=-5.052/( ( 7.126 + 7.212 )/ 2 )
=-5.052/7.169
=-70.47 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -70.47% mean?
Radnostix (INIS) has a ROC (Joel Greenblatt) % of -70.47% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Radnostix and its competitors. According to the industry distribution chart, Radnostix ranks #804 out of 983 companies in the Drug Manufacturers industry, placing it in the top 81.8%.
Is Radnostix's ROC (Joel Greenblatt) % too high?
Radnostix's current ROC (Joel Greenblatt) % is -70.47%. Based on the distribution chart, Radnostix ranks #804 out of 983 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Radnostix's ROC (Joel Greenblatt) % compare to SCYX and BTAI?
According to the Drug Manufacturers industry distribution chart, Radnostix ranks #804 out of 983 companies for ROC (Joel Greenblatt) %. This places Radnostix in the lower half of its industry. The industry median ROC (Joel Greenblatt) % is 11.46. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Drug Manufacturers company?
The median ROC (Joel Greenblatt) % among Drug Manufacturers companies is 11.46, based on 983 companies in the industry. Companies in the top quartile (top 25%) have a ROC (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Radnostix and its competitors. For the Drug Manufacturers industry, the median ROC (Joel Greenblatt) % is 11.46 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Radnostix's current ROC (Joel Greenblatt) % is -70.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radnostix stock overvalued right now?
Based on GuruFocus' analysis, Radnostix (INIS) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.05, compared to a current price of $0.06 — trading 20% above its estimated fair value. The current ROC (Joel Greenblatt) % is -70.47%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Radnostix (INIS), the current ROC (Joel Greenblatt) % is -70.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radnostix Business Description

Address 4137 Commerce Circle, Idaho Falls, ID, USA, 83401
Radnostix Inc manufactures a wide range of radioisotope-focused products used in a variety of medical and industrial applications. The company produces generic sodium iodide I-131 drug product, produces a variety of cobalt-60 products, and is in development to manufacture and sell medical devices for the nuclear medicine industry. Its business consists of five reportable segments, which include: Theranostics Products, Cobalt Products, Calibration & Reference Products, Medical Devices, and Fluorine Products. The majority of the revenue is derived from the Theranostics Products segment, which produces and distributes various isotopically pure radiopharmaceuticals, APIs, and radiochemicals for medical, industrial, and research applications.